Compounds & interventions

Stem cell therapy

Longevity & Aging · covered by 25 outlets this week · tracked since 2026-10-27

Press: 3 mainstream 67 specialist 42 independent outlet-days

What it is

Evidence 6/10 · mixed or limited trials Uneven · 1–10 by use Signals · regulator warning

Stem cell therapy uses cells that can renew themselves and become other cell types to repair or replace tissue. Proven uses are narrow: bone marrow and blood stem cell transplants for leukaemia, lymphoma and some blood disorders, plus a few approved products for skin, cornea and cartilage. Trials for Parkinson's, type 1 diabetes, heart failure and spinal injury are advancing, while an unregulated clinic industry sells unproven injections for joints, ageing and autism. Coverage here mixes the two, so check which the story describes.

Blood stem cell transplants for leukaemia, lymphoma and some blood disorders are a 10 on their own and have been used for decades. The score reflects everything else: Parkinson's, diabetes, heart disease and joints, where trials are early or have failed.

Evidence by use or claim · 1 preclinical to 10 thoroughly established

  1. Blood stem cell transplant (leukaemia, lymphoma, blood disorders)10/10 · thoroughly established

    Standard care since the 1970s; tens of thousands of transplants a year worldwide.

  2. Gene-edited blood stem cells for sickle cell and beta-thalassaemia8/10 · established for some uses

    Casgevy approved in the UK and US in 2023 after trials in a few dozen patients.

  3. Cornea and skin grafts (limbal stem cells, burns)8/10 · established for some uses

    Cultured limbal cells approved in Europe since 2015; cultured skin long used for burns.

  4. Type 1 diabetes (lab-grown islet cells)4/10 · early human evidence

    Small trials have freed some patients from insulin; phase 3 under way.

  5. Parkinson's disease3/10 · early human evidence

    First phase 1 and 2 results reported in 2025; safety established, benefit not yet.

  6. Heart disease2/10 · preclinical

    Large trials of bone-marrow cells (TIME, BOOST-2) found no benefit.

  7. Knees, joints and back pain2/10 · preclinical

    Mostly uncontrolled clinic series; the FDA treats these products as unapproved.

  8. Anti-ageing, autism and other clinic offerings1/10 · preclinical

    No controlled human evidence; the subject of FDA and FTC enforcement.

  • TrialHeart trials of bone-marrow cells (TIME, BOOST-2) found no improvement, and a twelve-trial meta-analysis found no significant benefit. source
  • RegulatorThe FDA has issued warning letters and sought court injunctions against clinics selling unapproved fat-derived cell products since 2018; the FTC ordered refunds for unsubstantiated claims. source
  • TrialIn 2021 at least twenty patients developed serious infections from umbilical cord blood products marketed as stem cell treatments. source
  • MarketHundreds of clinics in the US and abroad sell unproven stem cell injections for ageing, joints and autism; blood stem cell transplant remains the only widely practised approved form. source

Written by the Alivewire editors from the coverage below, 3d ago; rated 2d ago. Not medical advice; how the ratings work.

Coverage